Mirae Asset Global Investments Co. Ltd. Sells 10,834 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mirae Asset Global Investments Co. Ltd. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,086 shares of the specialty pharmaceutical company's stock after selling 10,834 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.14% of Jazz Pharmaceuticals worth $10,466,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company's stock valued at $825,705,000 after purchasing an additional 29,960 shares during the period. Wellington Management Group LLP raised its holdings in shares of Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company's stock valued at $408,654,000 after buying an additional 184,124 shares during the period. State Street Corp lifted its stake in Jazz Pharmaceuticals by 1.8% during the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company's stock worth $294,106,000 after acquiring an additional 42,703 shares in the last quarter. LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company's stock valued at $307,055,000 after acquiring an additional 55,630 shares during the period. Finally, FMR LLC boosted its holdings in Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company's stock valued at $172,560,000 after acquiring an additional 100,349 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:JAZZ traded down $2.91 during mid-day trading on Friday, hitting $110.58. The stock had a trading volume of 431,405 shares, compared to its average volume of 663,636. Jazz Pharmaceuticals plc has a 12-month low of $110.42 and a 12-month high of $147.14. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The company has a market cap of $6.97 billion, a PE ratio of 18.07, a P/E/G ratio of 1.57 and a beta of 0.59. The company's 50 day moving average is $121.21 and its 200-day moving average is $123.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. On average, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on JAZZ shares. Truist Financial restated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Barclays reduced their price objective on Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research note on Friday, March 1st. StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, January 30th. Robert W. Baird started coverage on Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They set an "outperform" rating and a $160.00 price target on the stock. Finally, Stifel Nicolaus lifted their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $195.08.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the business's stock in a transaction dated Friday, March 1st. The shares were acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company's stock, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the company's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.